Treatment of Severe or Symptomatic Hypercalcaemia in Inoperable or Persistent Parathyroid Carcinoma

Clinical Scenario

In patients with inoperable or persistent parathyroid carcinoma, severe or symptomatic hypercalcaemia is the dominant management challenge. Medical control of calcium is the primary treatment goal for those awaiting surgery and those for whom surgery is not an option.

Treatment Approach

Goal: reduction and control of serum calcium

Management combines an oral agent to control hypercalcaemia with intravenous hydration and a bone antiresorptive agent. Specific agent selection, preferred choices, and the complete dosing and sequencing algorithm are detailed in the full protocol.

Full regimen available via the protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.esmoop.2024.103664

Medical management of hypercalcaemia is the main treatment for patients awaiting surgery and those with inoperable PC.

The cornerstones of treatment for severe or symptomatic hypercalcaemia are intravenous saline hydration and bisphosphonate administration.

Cinacalcet is recommended to control hypercalcaemia [II, A].

The bone antiresorptive drug zoledronic acid is recommended as first-line treatment and should be preferred over pamidronate for severe or symptomatic hypercalcaemia [II, A].

The greatest reductions in calcium were reported in patients with the highest serum calcium levels before therapy.

View source ↗